TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21401214
Drug: Dimenhydrinate 40
Normalized name: dimenhydrinate 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 40 mg (monotherapy)
Study: 16584288
Drug: Fenofibrate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (250 mg sustained-release capsule) after overnight fasting
Study: 16584288
Drug: Fenofibrate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (250 mg sustained-release capsule) after standard breakfast
Study: 16584288
Drug: Fenofibrate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (250 mg sustained-release capsule) after high-fat breakfast
Study: 14563545
Drug: Subutex 2
Normalized name: Subutex 2mg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subutex 2 mg
Study: 14563545
Drug: Subutex 8
Normalized name: Subutex 8mg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subutex 8 mg
Study: 14563545
Drug: Subutex 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subutex 12 mg
Study: 14563545
Drug: Subutex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subutex 16 mg
Study: 14563545
Drug: Suboxone 8
Normalized name: Suboxone 8/2 Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboxone 8 mg/naloxone 2 mg
Study: 14563545
Drug: Naltrexone 50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50-150 mg
Study: 11090789
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day for 4 weeks
Study: 11090789
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 weeks followed by Losartan 50 mg/day for 4 weeks
Study: 8616130
Drug: Chlamydia trachomatis
Normalized name: CHLAMYDIA TRACHOMATIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in patients
Study: 8616130
Drug: Chlamydia trachomatis
Normalized name: CHLAMYDIA TRACHOMATIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in controls
Study: 15713143
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae antibodies
Study: 1329697
Drug: Org 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2766 (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Study: 1329697
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Study: 6426405
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for 2 years (in premenopausal status, after oophorectomy)
Study: 6426405
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with mitomycin C 20 mg/m2, iv, followed by cyclophosphamide 60 mg/m2, po
Study: 6426405
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamoxifen and chemotherapy
Study: 6426405
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone or combination of chemotherapy and tamoxifen
Study: 27759092
Drug: Mild electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 2 treatments per week for 12 weeks
Study: 27759092
Drug: Mild electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 4 treatments per week for 12 weeks
Study: 27759092
Drug: Mild electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week for 12 weeks
Study: 27759092
Drug: Mild electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment (combined groups)
Study: 27759092
Drug: Mild electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week
Study: 24509965
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate 0.015% gel
Study: 22744392
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for fungal keratitis
Study: 12940924
Drug: Azathioprine or
Normalized name: azathioprine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine or mercaptopurine (MP) treatment
Study: 10076125
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol combined with 50 microg gestodene
Study: 10076125
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol combined with 25 microg gestodene
Study: 10076125
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol combined with 25 microg gestodene (sequentially)
Study: 10076125
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol combined with 25 microg gestodene (continuously)
Study: 10076125
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol combined with 25 microg gestodene
Study: 2274626
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day to a maximum of 200 mg/day)
Study: 27814453
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily fluticasone (F)
Study: 27814453
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily fluticasone plus salmeterol (F + S)
Study: 27814453
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral montelukast (M)
Study: 26464041
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml ropivacaine 0.375%
Study: 26464041
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml isotonic saline
Study: 25306116
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea and vitamin C supplements
Study: 19304578
Drug: Larval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval therapy (bagged larvae, loose larvae)
Study: 11606914
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg anti-CD11a monoclonal antibody
Study: 9552136
Drug: Conventional pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pancreatic enzyme replacement therapy (3 capsules of 8,000 FIP units Creon)
Study: 9552136
Drug: High-lipase pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-lipase pancreatic enzyme replacement therapy (1 capsule of 25,000 FIP units)
Study: 7844208
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.5 mg/day LHRHa during folliculogenesis (group A)
Study: 7844208
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.1 mg/day LHRHa during folliculogenesis (group B)
Study: 29456086
Drug: Low-Dose Propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Propofol (LDP)
Study: 27425010
Drug: Insulin-dose-adjusted HbA1c
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dose-adjusted HbA1c level
Study: 15117578
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 2 seconds
Study: 15117578
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 4 seconds
Study: 15117578
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 2 seconds
Study: 15117578
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 4 seconds
Study: 15117578
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of regular insulin (0.15 U/kg)
Study: 15794740
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of valsartan and captopril
Study: 9172021
Drug: 20 cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 cm2 active patch delivering 50 micrograms/hr of fentanyl and a 30 cm2 placebo patch
Study: 9172021
Drug: 30 cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 cm2 active patch delivering 75 micrograms/hr of fentanyl and a 20 cm2 placebo patch
Study: 10624638
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA with morphine
Study: 3221377
Drug: Dietary salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary salt restriction (10 g to 2 g salt/day for five days)
Study: 3221377
Drug: Salt repletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt repletion (2 g salt/day to 20 g/day for five days)
Study: 23439604
Drug: darapladib 40
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: darapladib 40 mg
Study: 23439604
Drug: darapladib 80
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: darapladib 80 mg
Study: 23439604
Drug: darapladib 160
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: darapladib 160 mg
Study: 16995871
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil alone (treatment A)
Study: 16995871
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil co-administered with iron (treatment B)
Study: 16995871
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatments A and B
Study: 10417497
Drug: Fexofenadine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 80 mg, 120 mg, 180 mg
Study: 14623537
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg)
Study: 7590484
Drug: Toremifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (60 mg)
Study: 2175149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Indomethacin and Lisinopril
Study: 29444721
Drug: Group interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group interpersonal psychotherapy (IPT-G) delivered by lay community health workers (LCHWs), 12 sessions
Study: 29444721
Drug: Children of
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children of caregivers who received IPT-G
Study: 29444721
Drug: Caregivers receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregivers receiving treatment as usual (TAU)
Study: 29444721
Drug: Caregivers receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregivers receiving IPT-G
Study: 2054270
Drug: Levodopa/carbidopa combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa combination (Sinemet Plus)
Study: 6357631
Drug: 0.1mg Sulprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mg Sulprostone gel
Study: 6357631
Drug: 0.5mg PGE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg PGE2 gel
Study: 6357631
Drug: 0.05mg Sulprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05mg Sulprostone gel
Study: 22512481
Drug: Chemoradiotherapy (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (fluorouracil 500 mg/m²/day during fractions 1 to 5 and 16 to 20 of radiotherapy, mitomycin C 12 mg/m² on day 1)
Study: 20079760
Drug: Intervention (n=54):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (n=54): Supporters received monthly contacts from a counselor about providing effective support.
Study: 10382786
Drug: IL-1ra at
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1ra at a dose of 1 mg/kg/h (n = 20)
Study: 10382786
Drug: IL-1ra at
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1ra at a dose of 2 mg/kg/h (n = 22)
Study: 8808137
Drug: Standard 1-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 1-mg cigarette
Study: 25137036
Drug: trans-resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans-resveratrol (500 mg) three times per day for 90 days
Study: 15850121
Drug: Pen tablet
Normalized name: Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen tablet system for evaluation of hand motion control function; subjects instructed to tap 50 times with each hand.
Study: 12418296
Drug: Enoxaparin 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.8 mg/kg, subcutaneous every 12 hours during 5 days
Study: 12418296
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin during 5 days, by infusion
Study: 3254762
Drug: L-alanyl-L-glutamine
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-L-glutamine
Study: 3254762
Drug: Glycyl-L-tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyl-L-tyrosine
Study: 3254762
Drug: L-alanyl-L-glutamine and
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-L-glutamine and Glycyl-L-tyrosine
Study: 29576126
Drug: Fused B-mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fused B-mode and elastography videos with 0.25 ml volumes
Study: 29576126
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml volumes
Study: 29576126
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml volumes
Study: 23848989
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly (QW/QW)
Study: 23848989
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly (BIW/QW)
Study: 23848989
Drug: Etanercept (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (both dosing regimens)
Study: 20557313
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg aspirin per day for 6 months
Study: 20557313
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aspirin per day for 6 months
Study: 10739392
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of aspirin
Study: 18596733
Drug: High-dose epoetin-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epoetin-alpha
Study: 18596733
Drug: Low-dose epoetin-alpha
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epoetin-alpha
Study: 16059627
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray salmon calcitonin (CT‐NS)
Study: 11105068
Drug: Clonazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (2 mg/day)
Study: 10235588
Drug: Bismuth plus
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth plus metronidazole and amoxicillin (group A)
Study: 10235588
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus amoxicillin (group B)
Study: 10235588
Drug: H. pylori-positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori-positive patients post-treatment
Study: 1472937
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alpha 2B interferon (9 mU/week) in combination with oral chemotherapy
Study: 1472937
Drug: Oral chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chemotherapy only (control group)
Study: 6329567
Drug: Prednisone, azathioprine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, azathioprine, and OKT3 antibody
Study: 29288764
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus tivantinib (150 mg once daily and 360 mg twice daily)
Study: 27567363
Drug: Nifedipine (80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (80mg daily until labor, max 18 days)
Study: 11994701
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg twice daily)
Study: 10934090
Drug: Zafirlukast (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (80 mg twice daily)
Study: 11994701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of loratadine and zafirlukast
Study: 11994701
Drug: Zafirlukast alone
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast alone vs combination with loratadine
Study: 7843449
Drug: Alpha-blocker (bunazosin)
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker (bunazosin) 2 mg/d for 6 months
Study: 7843449
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets per day for 6 months)
Study: 1903599
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine infusion at graded rates (0 to 126 mmol/h)
Study: 1903599
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine infusion at 46.8 mmol/h
Study: 1903599
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine infusion
Study: 30597688
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.1, 0.2, 0.5, 1.0 mg/kg
Study: 30283029
Drug: Midazolam 0.045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.045 mg/kg (active placebo)
Study: 28768921
Drug: Evacetrapib 130
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 130 mg daily for 12 weeks
Study: 28768921
Drug: Placebo/atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/atorvastatin
Study: 26105582
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg/day) for 8 weeks in obese patients without T2DM
Study: 26105582
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg/day) for 8 weeks in obese patients with T2DM
Study: 26105582
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg/day) and pioglitazone (15 mg/day) combination for 8 weeks in obese patients with T2DM
Study: 24389932
Drug: Mild hyperthermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hyperthermia therapy (body core temperature 38.6 °C) combined with multimodal inpatient rehabilitation
Study: 22464343
Drug: Rapid genotyping
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid genotyping group (CYP2C19*2 carriers treated with 10 mg prasugrel daily)
Study: 22464343
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (CYP2C19*2 carriers treated with 75 mg clopidogrel daily)
Study: 20703198
Drug: Fluoxetine 10-60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10-60 mg/day for 12 weeks
Study: 20703198
Drug: Fluoxetine continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine continuation
Study: 15777603
Drug: Salmeterol HFA
Normalized name: Fluticasone-Salmeterol HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol HFA MDI 50 microg twice daily
Study: 15777603
Drug: Salmeterol CFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol CFC MDI 50 microg twice daily
Study: 12482334
Drug: Embolization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolization therapy with polyvinyl alcohol foam (Ivalon) as a single agent
Study: 12482334
Drug: Chemoembolization using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization using polyvinyl alcohol foam mixed with 750 mg/m2 of 5‐fluorouracil and 9 million units of interferon
Study: 9588435
Drug: Sumatriptan injection
Normalized name: sumatriptan Injection
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan injection (6 mg)
Study: 8575241
Drug: Indapamide treatment
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide treatment (2.5 mg)
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 6 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 12 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 24 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 36 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 48 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Study: 2243350
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.) at 60 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)